Alto Neuroscience, Stock Today
| ANRO Stock | 4.28 0.05 1.15% |
Performance0 of 100
| Odds Of DistressLess than 23
|
Alto Neuroscience, is selling at 4.28 as of the 29th of November 2024; that is 1.15% down since the beginning of the trading day. The stock's open price was 4.33. Alto Neuroscience, has about a 23 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. Equity ratings for Alto Neuroscience, are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 10th of December 2022 and ending today, the 29th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 2nd of February 2024 | Category Healthcare | Classification Health Care |
Alto Neuroscience, is entity of United States. It is traded as Stock on NYSE exchange. The company has 26.96 M outstanding shares of which 3.06 M shares are presently shorted by private and institutional investors with about 11.82 trading days to cover. More on Alto Neuroscience,
Moving together with Alto Stock
| 0.78 | HLN | Haleon plc | PairCorr |
| 0.77 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.76 | PFE | Pfizer Inc Aggressive Push | PairCorr |
| 0.74 | SHG | Shinhan Financial | PairCorr |
Moving against Alto Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Alto Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CoFounder CEO | B BCom | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Ideas | (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NYSE Composite, Computers, Biotech, Health Management, Health Care, Pharmaceuticals, Biotechnology, Healthcare, Computing (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Alto Neuroscience, can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Alto Neuroscience,'s financial leverage. It provides some insight into what part of Alto Neuroscience,'s total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Alto Neuroscience, (ANRO) is traded on New York Stock Exchange in USA. It is located in 369 South San Antonio Road, Los Altos, CA, United States, 94022 and employs 11 people. Alto Neuroscience, is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 367.18 M. Alto Neuroscience, conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 26.96 M outstanding shares of which 3.06 M shares are presently shorted by private and institutional investors with about 11.82 trading days to cover.
Alto Neuroscience, generates negative cash flow from operations
Check Alto Neuroscience, Probability Of Bankruptcy
Ownership AllocationAlto Neuroscience, holds a total of 26.96 Million outstanding shares. The majority of Alto Neuroscience, outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Alto Neuroscience, to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Alto Neuroscience,. Please pay attention to any change in the institutional holdings of Alto Neuroscience, as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Alto Ownership Details
Alto Neuroscience, Historical Income Statement
Alto Stock Against Markets
Alto Neuroscience, Corporate Management
| Melissa Berman | Vice Accounting | Profile | |
| Michael MBA | Chief Officer | Profile | |
| Jason Hoffman | Vice Resources | Profile | |
| Erin JD | General Officer | Profile |
Already Invested in Alto Neuroscience,?
The danger of trading Alto Neuroscience, is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Alto Neuroscience, is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Alto Neuroscience,. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Alto Neuroscience, is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Alto Neuroscience, offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Alto Neuroscience,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Alto Neuroscience, Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Alto Neuroscience, Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alto Neuroscience,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Alto Stock, please use our How to Invest in Alto Neuroscience, guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alto Neuroscience,. If investors know Alto will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alto Neuroscience, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.85) |
The market value of Alto Neuroscience, is measured differently than its book value, which is the value of Alto that is recorded on the company's balance sheet. Investors also form their own opinion of Alto Neuroscience,'s value that differs from its market value or its book value, called intrinsic value, which is Alto Neuroscience,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alto Neuroscience,'s market value can be influenced by many factors that don't directly affect Alto Neuroscience,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alto Neuroscience,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Alto Neuroscience, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alto Neuroscience,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.